港股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

恒瑞医药

82.850

-1.450-1.72%

成交量：372.79万

成交额：3.08亿

市值：5,498.75亿

市盈率：76.03

高：85.100

开：81.700

低：80.850

收：84.300

52周最高：95.200

52周最低：52.500

股本：66.37亿

香港流通股本：2.58亿

量比：1.84

换手率：1.44%

股息：- -

股息率：- -

每股收益(LYR):1.090

净资产收益率：14.41%

总资产收益率：8.45%

市净率：8.63

市盈率(LYR):76.03

市销率: 16.74

数据加载中...

总览公司新闻公告

格隆汇港股回购榜 | 10月13日

又一个“全球首款”减肥药来了，但胖子快要不够用了

恒瑞重返第一，百利天恒首登，六成公司“新晋”，谁在定义药企竞争力？2025年竞争力20强揭榜

国产PDE4抑制剂破局上市，银屑病治疗迎来“中国方案”

CPHI制药在线

2025年医药研发行业发展现状及未来趋势展望分析

恒瑞医药(01276)10月13日耗资1135.27万元回购17万股A股

恒瑞医药拟10月27日举行董事会会议审批季度业绩

格隆汇资讯

恒瑞医药：董事会会议通告

香港交易所

每日卖空追踪 | 恒瑞医药 10月13日卖空量成交9.88万股，卖空比例为2.65%

2025-2030处方药行业：创新药与国产替代

智通AH统计|10月13日

关注三季度业绩预期和底部个股

向阳论医谈药

十一批集采推迟；康泰医学被美国禁售；复星恒瑞绿叶高管变动

郑大一附院：与恒瑞医药签署战略合作协议

生物医学发展迎来顶层催化！创新药行业方兴未艾

某医药一哥的“鸡贼”式MBO。

礼来、AZ高管“出走”，恒瑞、绿叶“抢人”。药圈大咖们为何密集履新？

天风Weekly · 深度研报汇览·20251011

2025年中国西药行业竞争分析及未来发展前景趋势预测，规模扩张

2024年院内销售13732亿元，阿斯利康、恒瑞医药、辉瑞三强鼎立

摩熵医药大数据

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/01276/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"01276","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"01276\",,,,,undefined,":{"symbol":"01276","market":"HK","secType":"STK","nameCN":"恒瑞医药","latestPrice":82.85,"timestamp":1760342908003,"preClose":84.3,"halted":0,"volume":3727916,"delay":0,"floatShares":258000000,"shares":6637000000,"eps":1.0897138678408615,"marketStatus":"未开盘","change":-1.45,"latestTime":"10-13 16:08:28","open":81.7,"high":85.1,"low":80.85,"amount":307972938,"amplitude":0.050415,"askPrice":82.85,"askSize":6600,"bidPrice":82.8,"bidSize":600,"shortable":3,"etf":0,"ttmEps":1.2646238407679982,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1760405400000},"marketStatusCode":0,"adr":0,"listingDate":1747929600000,"exchange":"SEHK","adjPreClose":84.3,"openAndCloseTimeList":[[1760319000000,1760328000000],[1760331600000,1760342400000]],"volumeRatio":1.8417769277965432,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"600276","market":"SH","secType":"STK","nameCN":"恒瑞医药","latestPrice":66.98,"timestamp":1760338800000,"preClose":68.2,"halted":0,"volume":53228700,"delay":0,"premium":"+13.51"}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"01276\",,,,,undefined,":{"symbol":"01276","floatShares":258000000,"roa":"8.45%","roe":"14.41%","lyrEps":1.089714,"volumeRatio":1.8417769277965432,"shares":6637000000,"dividePrice":0,"high":85.1,"amplitude":0.050415,"preClose":84.3,"low":80.85,"week52Low":52.5,"pbRate":"8.63","psRate":"16.74","week52High":95.2,"institutionHeld":0,"latestPrice":82.85,"committee":-0.833333,"eps":1.0897138678408615,"divideRate":0,"volume":3727916,"delay":0,"ttmEps":1.2646238407679982,"open":81.7,"prevYearClose":44.05,"prevWeekClose":84.3,"prevMonthClose":88.8,"prevQuarterClose":88.8,"fiveDayClose":93.9,"twentyDayClose":83.1,"sixtyDayClose":71.7,"earningDate":1761580800000},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/01276\",params:#limit:5,,,undefined,":[{"date":"2025-10-28","symbol":"01276","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1761615000000,"name":null,"time":"","dateTimestamp":1761580800000,"actualEps":null},{"date":"2025-08-21","symbol":"01276","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1755739800000,"name":null,"time":"","dateTimestamp":1755705600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"01276\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"01276\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.6667,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":6,"updateTime":1759161600000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/01276\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"01276","date":"2025-10-10","current":65.497911,"percent":0.683673,"low":50.027905,"twenty":52.193561,"median":59.039802,"eighty":62.657943,"high":65.582363,"avg":57.860175,"sd":5.048392,"marketCap":496019912951.91},"quantilePoints":[{"date":"2025-05-23","current":52.570963,"twenty":52.783176,"median":53.101495,"eighty":53.419815,"marketCap":390693388207.53},{"date":"2025-05-30","current":53.015805,"twenty":51.822085,"median":52.540895,"eighty":52.926837,"marketCap":395731540422.24},{"date":"2025-06-06","current":52.120101,"twenty":52.130014,"median":52.555929,"eighty":53.075252,"marketCap":390038198012.59},{"date":"2025-06-13","current":52.209491,"twenty":52.177631,"median":52.691227,"eighty":53.357137,"marketCap":390861633032.23},{"date":"2025-06-20","current":50.172412,"twenty":51.591196,"median":52.469796,"eighty":53.075252,"marketCap":374874997562.85},{"date":"2025-06-27","current":50.314776,"twenty":50.363569,"median":52.169666,"eighty":53.013533,"marketCap":376991477472.78},{"date":"2025-07-04","current":51.666141,"twenty":50.343584,"median":52.120101,"eighty":53.004446,"marketCap":387134991658.26},{"date":"2025-07-11","current":55.507007,"twenty":50.44351,"median":52.13337,"eighty":53.090114,"marketCap":415495681161.23},{"date":"2025-07-18","current":57.272274,"twenty":50.582121,"median":52.209491,"eighty":54.057606,"marketCap":428373566715.29},{"date":"2025-07-25","current":54.897923,"twenty":50.594414,"median":52.555929,"eighty":55.711415,"marketCap":412107620053.2},{"date":"2025-08-01","current":59.731878,"twenty":50.855059,"median":52.994419,"eighty":55.972407,"marketCap":445624526286.47},{"date":"2025-08-08","current":59.478715,"twenty":51.107295,"median":53.05296,"eighty":56.541585,"marketCap":444845815775.64},{"date":"2025-08-15","current":61.917611,"twenty":51.356483,"median":53.519848,"eighty":59.478715,"marketCap":462392609292.46},{"date":"2025-08-22","current":58.782188,"twenty":51.569512,"median":54.477764,"eighty":60.15932,"marketCap":470428104569.66},{"date":"2025-08-29","current":59.85298,"twenty":51.666141,"median":55.691374,"eighty":59.937003,"marketCap":481284287403.35},{"date":"2025-09-05","current":65.582363,"twenty":51.677932,"median":55.770266,"eighty":60.732448,"marketCap":526832269752.24},{"date":"2025-09-12","current":62.481332,"twenty":51.8337,"median":55.972407,"eighty":61.285609,"marketCap":502824785657.99},{"date":"2025-09-19","current":63.179889,"twenty":52.120101,"median":56.254853,"eighty":61.852995,"marketCap":508085671393.42},{"date":"2025-09-26","current":63.528382,"twenty":52.146639,"median":56.965096,"eighty":62.270337,"marketCap":509562668601.01},{"date":"2025-10-03","current":64.989073,"twenty":52.165061,"median":57.272274,"eighty":62.504861,"marketCap":522523002865.02},{"date":"2025-10-10","current":61.782766,"twenty":52.193561,"median":59.039802,"eighty":62.657943,"marketCap":496019912951.91}],"updateTime":1760382886668},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"01276\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2575234944","title":"格隆汇港股回购榜 | 10月13日","url":"https://stock-news.laohu8.com/highlight/detail?id=2575234944","media":"格隆汇","labels":["buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575234944?lang=zh_cn&edition=fundamental","pubTime":"2025-10-14 08:00","pubTimestamp":1760400000,"startTime":"0","endTime":"0","summary":"其中，回购金额最大的为美的集团，回购数量418.24万 ，回购金额3.00亿。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2025/10/14080053596994.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"buyback","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU2476274720.SGD","02273","06098","LU0594300179.USD","02512","BK1114","00799","00103","01986","06613","00418","00798","06868","02369","00393","01945","XIACY","00386","00300","02142","09979","02306","01276","03309","BK1515","LU0441854154.USD","00732","02158","08128","08188","06609","01810","06655","02517","09959","HXXD.SI","MIUmain","00697","09922","00947","00345","02121","BK1604","81810","00289","01672","09966","01328","03669","02190"],"gpt_icon":1},{"id":"2575624233","title":"又一个“全球首款”减肥药来了，但胖子快要不够用了","url":"https://stock-news.laohu8.com/highlight/detail?id=2575624233","media":"健识局","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575624233?lang=zh_cn&edition=fundamental","pubTime":"2025-10-13 20:34","pubTimestamp":1760358862,"startTime":"0","endTime":"0","summary":"全球首款偏向型减肥药目前市面上已经问世的减肥药，比如司美格鲁肽、替尔泊肽基本都是GLP-1受体激动剂，而先为达的核心产品埃诺格鲁肽是一种偏向性GLP-1RA减重药。作为对比，礼来的替尔泊肽最高剂量15mg的第52周减重约15.1%；诺和诺德的司美格鲁肽在治疗68周后，患者平均体重下降14.9%。对此，有投资者打趣，以后减肥药太多，胖子快要不够用了。先为达生物这样还在冲击ipo的减肥药企业，想要从“诸神混战”中脱颖而出，并不容易。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251013210657a6b727ec&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251013210657a6b727ec&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1023057109.AUD","LU0359201885.HKD","LU0359202008.SGD","91078","LU2543165471.USD","LU0359201612.USD","01276","BK1191"],"gpt_icon":0},{"id":"2575336762","title":"恒瑞重返第一，百利天恒首登，六成公司“新晋”，谁在定义药企竞争力？2025年竞争力20强揭榜","url":"https://stock-news.laohu8.com/highlight/detail?id=2575336762","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575336762?lang=zh_cn&edition=fundamental","pubTime":"2025-10-13 20:08","pubTimestamp":1760357280,"startTime":"0","endTime":"0","summary":"医药行业正从“增量时代”过渡到“存量竞争”，韧性成为药企新竞争力，涵盖修复力、适应力与再生力。这种能力不仅体现在账面业绩稳定，更在于结构上的自我调整，如产品结构切换、商业模型重新配置及组织管理弹性。2024年，医药行业持续调整，表现不振，但仍有众多优秀公司逆周期增长。2025年中国医药上市公司竞争力20强展示了具备“穿越周期”潜力的药企，它们主动求变，承受压力并快速“修复”。面对行业结构性拐点，药企需从产品创新、商业卓越、动态管理三方面入手，实现韧性发展。2025年榜单新上榜公司增至12家，过半公司变动，凸显行业变化。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251014011436972ba8f4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251014011436972ba8f4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1023057109.AUD","01276","BK1191","LU0359202008.SGD","91194","LU0359201612.USD","LU2543165471.USD","LU0359201885.HKD"],"gpt_icon":0},{"id":"2575690233","title":"国产PDE4抑制剂破局上市，银屑病治疗迎来“中国方案”","url":"https://stock-news.laohu8.com/highlight/detail?id=2575690233","media":"CPHI制药在线","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575690233?lang=zh_cn&edition=fundamental","pubTime":"2025-10-13 18:08","pubTimestamp":1760350102,"startTime":"0","endTime":"0","summary":"关注并星标CPHI制药在线2025年10月11日，国家药监局官网显示，和美药业研发的1类新药“莫米司特”正式获批上市，用于治疗斑块状银屑病。这不仅是中国首个自主研发的PDE4抑制剂，也标志着国产创新药在自身免疫疾病领域迈出了关键一步。终于在 2025 年 10 月 11 日，国家药监局官网显示，莫米司特片获批上市，成为首款获批的国产 PDE4 抑制剂。在莫米司特获批之前，国内 PDE4 抑制剂市场已有两款进口药物占据一席之地。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251013182436a45d796f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251013182436a45d796f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2543165471.USD","LU1023057109.AUD","BK1191","01276","LU0359201612.USD","LU0359201885.HKD","LU0359202008.SGD"],"gpt_icon":0},{"id":"2575233640","title":"2025年医药研发行业发展现状及未来趋势展望分析","url":"https://stock-news.laohu8.com/highlight/detail?id=2575233640","media":"中研网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575233640?lang=zh_cn&edition=fundamental","pubTime":"2025-10-13 17:30","pubTimestamp":1760347853,"startTime":"0","endTime":"0","summary":"2025年医保目录首次纳入“商业健康保险创新药品目录”，部分高价值药物可通过商保报销，提升可及性。如需获取完整版报告及定制化战略规划方案，请查看中研普华产业研究院的《中国医药研发行业“十五五”未来趋势预测报告》。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251013173100a6b6da88&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251013173100a6b6da88&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01276","BK1574","09939","LU0359201885.HKD","BK1161","LU0359201612.USD","BK1515","LU1023057109.AUD","LU2543165471.USD","LU0359202008.SGD","BK1191"],"gpt_icon":0},{"id":"2575647684","title":"恒瑞医药(01276)10月13日耗资1135.27万元回购17万股A股","url":"https://stock-news.laohu8.com/highlight/detail?id=2575647684","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575647684?lang=zh_cn&edition=fundamental","pubTime":"2025-10-13 16:48","pubTimestamp":1760345298,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(01276)公布，2025年10月13日耗资1135.27万元回购17万股A股股份。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1354259.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0196","LU2488822045.USD","LU0359201885.HKD","LU1997244956.HKD","LU2495084118.USD","BK1191","BK0239","LU1023057109.AUD","LU2543165471.USD","BK0183","BK0028","399300","LU2580892862.HKD","LU0405327494.USD","LU1064130708.USD","LU2289578879.USD","600276","LU0359201612.USD","LU1655091616.SGD","LU0359202008.SGD","LU2328871848.SGD","LU2580892789.USD","LU2148510915.USD","BK0060","LU1064131003.USD","159982","BK0012","LU1328615791.USD","LU0405327148.USD","LU1997245094.SGD","LU1255011170.USD","01276","LU1969619763.USD","BK0188","LU1997245177.USD"],"gpt_icon":0},{"id":"2575233621","title":"恒瑞医药拟10月27日举行董事会会议审批季度业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2575233621","media":"格隆汇资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575233621?lang=zh_cn&edition=fundamental","pubTime":"2025-10-13 16:34","pubTimestamp":1760344488,"startTime":"0","endTime":"0","summary":"格隆汇10月13日丨恒瑞医药(01276.HK)宣布，董事会会议将于2025年10月27日(星期一)举行，藉以(其中包括)考虑及批准本公司及其附属公司截至2025年9月30日止九个月的季度业绩及其发布。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025101316350394c6201a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025101316350394c6201a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1023057109.AUD","LU0359201885.HKD","BK1191","01276","LU0359202008.SGD","LU2543165471.USD","LU0359201612.USD"],"gpt_icon":0},{"id":"2575723364","title":"恒瑞医药：董事会会议通告","url":"https://stock-news.laohu8.com/highlight/detail?id=2575723364","media":"香港交易所","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575723364?lang=zh_cn&edition=fundamental","pubTime":"2025-10-13 16:30","pubTimestamp":1760344223,"startTime":"0","endTime":"0","summary":"江苏恒瑞医药股份有限公司于2025年10月13日宣布，将于2025年10月27日（星期一）召开董事会会议，主要议程为审议及批准公司及其附属公司截至2025年9月30日止九个月的季度业绩，并讨论相关业绩发布事宜。本次会议由董事长孙飘扬先生召集，现任董事会成员包括6名执行董事、1名非执行董事及4名独立非执行董事。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251013164128a45d521a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251013164128a45d521a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","LU0359201612.USD","LU0359202008.SGD","LU1023057109.AUD","LU2543165471.USD","LU0359201885.HKD","01276"],"gpt_icon":0},{"id":"2575233664","title":"每日卖空追踪 | 恒瑞医药 10月13日卖空量成交9.88万股，卖空比例为2.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2575233664","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575233664?lang=zh_cn&edition=fundamental","pubTime":"2025-10-13 16:30","pubTimestamp":1760344220,"startTime":"0","endTime":"0","summary":"恒瑞医药北京时间10月13日，跌1.72%，卖空量成交9.88万股，较上一交易日减少75.06%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251013163218a45d4e2f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251013163218a45d4e2f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1023057109.AUD","LU0359201885.HKD","BK1191","01276","LU0359202008.SGD","LU2543165471.USD","LU0359201612.USD"],"gpt_icon":0},{"id":"2575240561","title":"2025-2030处方药行业：创新药与国产替代","url":"https://stock-news.laohu8.com/highlight/detail?id=2575240561","media":"中研网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575240561?lang=zh_cn&edition=fundamental","pubTime":"2025-10-13 16:18","pubTimestamp":1760343507,"startTime":"0","endTime":"0","summary":"2025-2030处方药行业：创新药与国产替代前言在全球人口老龄化加速、慢性病负担加重以及生物技术突破的多重驱动下，处方药市场正经历结构性变革。2025年以来，医保谈判成功率维持高位，高价肿瘤药通过降价纳入医保后销量激增，显著释放市场需求。(三)需求环境：老龄化与慢性病驱动市场扩容根据中研普华研究院《2025-2030年处方药市场发展现状调查及供需格局分析预测报告》显示：全球65岁以上人口预计将在2030年突破15亿，慢性病发病率持续攀升。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251013161832a45d47c5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251013161832a45d47c5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0588546209.SGD","BK1500","06160","BK1574","LU1719994722.HKD","LU1770034418.SGD","LU1969619763.USD","LU0307460666.USD","BK1583","BK1588","LU1251922891.USD","LU1303224171.USD","LU2328871848.SGD","BK1161","02196","06978","01276"],"gpt_icon":0},{"id":"2575473442","title":"智通AH统计|10月13日","url":"https://stock-news.laohu8.com/highlight/detail?id=2575473442","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575473442?lang=zh_cn&edition=fundamental","pubTime":"2025-10-13 16:15","pubTimestamp":1760343305,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，截止10月13日收盘，东北电气、弘业期货、安德利果汁分列AH溢价率前三位，溢价率分别为757.14%、233.76%、230.75%；宁德时代、恒瑞医药、招商银行分列AH溢价率末三位，溢价率分别为-18.07%、-3.16%、4.43%。其中三花智控、中远海发、康龙化成的偏离值位居前三，分别为20.82%、17.57%、15.35%；另外，东北电气、上海电气、秦港股份的偏离值位居后三，分别为-56.53%、-21.93%、-11.51%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1354224.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0348825331.USD","03750","LU1211504680.USD","00525","02009","02050","03606","03678","01138","03143","00916","03759","01033","02866","LU0417516902.SGD","01057","00107","00187","00338","00300","02218","00914","01988","01276","BK1563","01349","LU0359202008.SGD","00168","159982","03369","00588","BK1137","00553","LU0456846285.SGD","399300","01812","02603","02338","LU1880383440.USD","00042","01108","01528","03968","LU0501845795.SGD","LU1242518857.USD","00598"],"gpt_icon":1},{"id":"2575328207","title":"关注三季度业绩预期和底部个股","url":"https://stock-news.laohu8.com/highlight/detail?id=2575328207","media":"向阳论医谈药","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575328207?lang=zh_cn&edition=fundamental","pubTime":"2025-10-13 15:17","pubTimestamp":1760339871,"startTime":"0","endTime":"0","summary":"截至目前，已获批用于MASH适应症治疗的药物仅包括Madrigal的THRβ激动剂resmetirom以及诺和诺德的GLP-1RA司美格鲁肽。2025年初以来至今，医药行业上涨21.87%，跑赢沪深300指数4.54个百分点，行业涨跌幅排名第12。此外，在EFX获批用于治疗MASH引起的代偿性肝硬化后，持有人有权获得总价值5亿美元的现金额外支付。本次收购最高总价达52亿美元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251013152416a6b6a573&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251013152416a6b6a573&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01276","BK1191","06887"],"gpt_icon":0},{"id":"2575106954","title":"十一批集采推迟；康泰医学被美国禁售；复星恒瑞绿叶高管变动","url":"https://stock-news.laohu8.com/highlight/detail?id=2575106954","media":"健识局","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575106954?lang=zh_cn&edition=fundamental","pubTime":"2025-10-12 19:05","pubTimestamp":1760267154,"startTime":"0","endTime":"0","summary":"另外，第十一批药品集采的开标时间延期至10月27日。此前，联采办曾公布第十一批国家药品集采的开标时间是10月21日，调整后推迟了6天。医药卫生事件1.复星、恒瑞、绿叶高管变动10月9日，康桥资本发布公告，原复星医药董事长吴以芳正式加盟，出任执行运营合伙人。9月27日，云南省昭通市纪委监委消息称，昭通市第一人民医院原党委副书记、院长郭昌贵涉嫌严重违纪违法，已主动投案，目前正接受市纪委监委纪律审查和监察调查。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251012190916a45bd4de&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251012190916a45bd4de&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0359202008.SGD","LU0359201885.HKD","01276","LU1023057109.AUD","LU2543165471.USD","LU0359201612.USD","BK1191"],"gpt_icon":0},{"id":"2575441066","title":"郑大一附院：与恒瑞医药签署战略合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2575441066","media":"器械之家","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575441066?lang=zh_cn&edition=fundamental","pubTime":"2025-10-12 17:00","pubTimestamp":1760259618,"startTime":"0","endTime":"0","summary":"本次恒瑞医药与郑大附一签订战略合作协议也有豪森/翰森的高管同行。为深入贯彻健康中国战略，加速医药创新成果转化，推动我院临床研究与诊疗水平协同提升，10月9日上午，我院与江苏恒瑞医药股份有限公司在东院区正式签署战略合作协议。在全场见证下，恒瑞医药总裁冯佶与我院院长余祖江分别代表双方签署战略合作协议书；孙飘扬董事长与王福伟书记互赠纪念品，标志着双方合作正式迈入新阶段。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251012173606a6b54244&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251012173606a6b54244&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0359202008.SGD","LU2543165471.USD","LU0359201612.USD","01276","LU0359201885.HKD","BK1191","LU1023057109.AUD"],"gpt_icon":1},{"id":"2575699410","title":"生物医学发展迎来顶层催化！创新药行业方兴未艾","url":"https://stock-news.laohu8.com/highlight/detail?id=2575699410","media":"巨丰投顾","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575699410?lang=zh_cn&edition=fundamental","pubTime":"2025-10-12 10:22","pubTimestamp":1760235779,"startTime":"0","endTime":"0","summary":"受益于国内政策、出海授权、业绩增速，创新药行业基本面持续向好。创新药行业未来发展趋势政策端，审评审批持续提质增效，临床试验申请30日内审评等举措加速转化，医保动态调整与商保创新药目录拓宽支付路径，降低企业回报不确定性。国信证券指出，2025年上半年A股医药行业营收、利润同比小幅下滑，但创新药及产业链景气度较高。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251012102639a45b5086&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251012102639a45b5086&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0359201612.USD","LU0359201885.HKD","LU2543165471.USD","BK1191","BK1574","01276","06978","LU1023057109.AUD","BK1161","LU0359202008.SGD"],"gpt_icon":0},{"id":"2575410690","title":"某医药一哥的“鸡贼”式MBO。","url":"https://stock-news.laohu8.com/highlight/detail?id=2575410690","media":"医药财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575410690?lang=zh_cn&edition=fundamental","pubTime":"2025-10-12 08:15","pubTimestamp":1760228156,"startTime":"0","endTime":"0","summary":"经过这一系列操作，孙飘扬成为天宇医药的第一大股东。在业界，豪森药业长期被视为恒瑞医药的“影子公司”，十余年来关于“夫妻店”、涉嫌利益输送的质疑从未间断。流传于内部的这份声明中特别指出：1998-2005年间的中小国企“改制潮” 因监管制度不完善成为资产流失重灾区，正是恒瑞医药MBO发生的时间段。恒瑞医药的MBO案例揭示了国企改制中一个普遍存在的问题：通过表面合规的程序，实现实质上的资产转移。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251012082310a6b4b9fc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251012082310a6b4b9fc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09939","LU0359202008.SGD","BK1515","LU2543165471.USD","BK1161","01276","LU0359201612.USD","BK1191","BK1574","LU1023057109.AUD","LU0359201885.HKD"],"gpt_icon":0},{"id":"2574469233","title":"礼来、AZ高管“出走”，恒瑞、绿叶“抢人”。药圈大咖们为何密集履新？","url":"https://stock-news.laohu8.com/highlight/detail?id=2574469233","media":"E药经理人","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574469233?lang=zh_cn&edition=fundamental","pubTime":"2025-10-11 22:48","pubTimestamp":1760194110,"startTime":"0","endTime":"0","summary":"据悉，尹航将直接汇报于总裁冯佶，并进入公司管委会。仅2025年上半年，恒瑞就已经已完成3笔重大对外授权交易。今年9月，恒瑞还正式启动了2026全球精英计划，这是一项专为海外人才打造的定制化培养项目。在尹航履新恒瑞同期，绿叶制药也宣布了艾伯维中国区前总经理欧思朗的加入。事实上，欧思朗并非绿叶首次引入具有跨国药企从业背景的高端人才。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251011225330a45ac13d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251011225330a45ac13d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0359201612.USD","01276","LU2543165471.USD","LU1023057109.AUD","BK1191","LU0359201885.HKD","LU0359202008.SGD"],"gpt_icon":0},{"id":"2574245131","title":"天风Weekly · 深度研报汇览·20251011","url":"https://stock-news.laohu8.com/highlight/detail?id=2574245131","media":"天风研究","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574245131?lang=zh_cn&edition=fundamental","pubTime":"2025-10-11 18:54","pubTimestamp":1760180081,"startTime":"0","endTime":"0","summary":"观察本轮黄金牛市，万得黄金行业指数与金价波动基本一致，且在2024年之前并未展现出较高的弹性。当前以WIND全A为股票配置主体的绝对收益产品建议仓位至80%。“政府关门”令美联储年内再降息2次的预期升温。政府关门对就业和GDP造成负面打击。2）温等静压机：工作温度一般不超过500℃，压强范围可达300MPa左右。2024年，民爆生产企业累计完成生产总值416.95亿元，累计实现利润总额96.39亿元，工业炸药产销量分别为449万吨、448.5万吨。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251011193557a6b41b31&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251011193557a6b41b31&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02137","01093","01276","BK1161","02509"],"gpt_icon":0},{"id":"2574456298","title":"2025年中国西药行业竞争分析及未来发展前景趋势预测，规模扩张","url":"https://stock-news.laohu8.com/highlight/detail?id=2574456298","media":"中研网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574456298?lang=zh_cn&edition=fundamental","pubTime":"2025-10-11 17:33","pubTimestamp":1760175181,"startTime":"0","endTime":"0","summary":"在“健康中国2030”战略纲领指引下，行业发展的底层逻辑已从单纯的规模扩张，转变为以临床价值、技术创新和成本效益为核心的新范式。核心发现与关键数据：市场规模： 正如中研普华产业研究院在《2025-2030年中国西药行业竞争分析及发展前景预测报告》中指出的，预计到2030年，中国西药市场规模将突破2.5万亿元人民币，2025-2030年复合年均增长率将维持在5%-7%的中高速区间。预计到2027年，市场规模有望达到2万亿元，2030年迈向2.5万亿元大关。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251011173303a45a69eb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251011173303a45a69eb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02359","BK1161","BK1141","LU1046422090.SGD","LU0708995583.HKD","BK1574","LU0320764599.SGD","LU2045819591.USD","LU2242644610.SGD","LU0052750758.USD","01276","BK1583","LU2125910500.SGD","BK1576","06978"],"gpt_icon":0},{"id":"2574692354","title":"2024年院内销售13732亿元，阿斯利康、恒瑞医药、辉瑞三强鼎立","url":"https://stock-news.laohu8.com/highlight/detail?id=2574692354","media":"摩熵医药大数据","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574692354?lang=zh_cn&edition=fundamental","pubTime":"2025-10-11 15:48","pubTimestamp":1760168912,"startTime":"0","endTime":"0","summary":"与2023年同期相比，除抗肿瘤药和免疫机能调节药、消化系统与代谢药物、呼吸系统类药物份额保持稳定或增长外，其余品类均呈现不同程度下滑。结语2024年全终端医院药品销售市场，化学药和生物药持续发力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251011155600a6b3daa1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251011155600a6b3daa1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","LU1023057109.AUD","01276","LU0359201885.HKD","LU0359201612.USD","LU0359202008.SGD","LU2543165471.USD"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":200,"code":"91000000","status":"200"}]}}